Effects of ibandronate on bone quality: Preclinical studies

Bone

Volumn 40, Issue 2, 2007, Pages 265-273

  Bauss, F ^a   Dempster, D W ^b  

^a ROCHE DIAGNOSTICS GMBH   (Germany)

^b HELEN HAYES HOSPITAL   (United States)

Author keywords

Bone quality; Ibandronate; Intermittent; Preclinical; Safety

Indexed keywords

ALENDRONIC ACID; IBANDRONIC ACID; PLACEBO;

BIOMECHANICS; BONE DENSITY; BONE FRAGILITY; BONE MASS; BONE STRENGTH; CLINICAL TRIAL; DISEASE MODEL; DOSAGE SCHEDULE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; EVALUATION; FRACTURE; HUMAN; MULTIPLE CYCLE TREATMENT; NONHUMAN; OSTEOPENIA; OSTEOPOROSIS; REVIEW; RISK REDUCTION;

ANIMALS; BIOMECHANICS; BONE AND BONES; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE REMODELING; CALCIFICATION, PHYSIOLOGIC; DIPHOSPHONATES; DISEASE MODELS, ANIMAL; DOGS; DRUG EVALUATION, PRECLINICAL; HAPLORHINI; OSTEOPOROSIS; RATS;

EID: 33846140473     PISSN: 87563282     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bone.2006.08.002     Document Type: Review

References (62)

1. Committee for Proprietary Medicinal Products (CPMP). Note for guidance on involutional osteoporosis in women. London, European Agency for the Evaluation of Medicinal Products, Human Medicines Evaluation Unit 2001.
2. Wasnich R.D., Ross P.D., Davis J.W., and Vogel J.M. A comparison of single and multi-site BMC measurements for assessment of spine fracture probability. J. Nucl. Med. 30 (1989) 1166-1171
3. Chesnut C.H., and Rosen C.J. Reconsidering the effects of antiresorptive therapies in reducing osteoporotic fracture. J. Bone Miner. Res. 16 (2001) 2163-2172
4. Cummings S.R., Karpf D.B., Harris F., Genant H.K., Ensrud K., LaCroix A.Z., et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am. J. Med. 112 (2002) 281-289
5. Ammann P., and Rizzoli R. Bone strength and its determinants. Osteoporos. Int. 14 Suppl. 3 (2003) S13-S18
6. Järvinen T.L.N., Sievänen H., Jokihaara J., and Einhorn T.A. Revival of bone strength; the bottom line. J. Bone Miner. Res. 20 (2005) 717-720
7. National Institutes of Health. Osteoporosis prevention, diagnosis, and therapy. NIH Consens. Statement 17 (2000) 1-45
8. United States Food and Drug Administration (FDA). Guidelines for preclinical and clinical evaluation of agents used in the prevention or treatment of postmenopausal osteoporosis (1994), U.S. Food and Drug Administration, Rockville, MD
9. Felsenberg D., and Boonen S. The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management. Clin. Ther. 27 (2005) 1-11
10. Riggs B.L., and Parfitt A.M. Perspective. Drugs used to treat osteoporosis: the critical need for a uniform nomenclature based on their action on bone remodeling. J. Bone Miner. Res. 20 (2005) 177-184
11. Wallach S., Feinblatt J.D., and Aviola L.V. The 'bone quality' problem. Calcif. Tissue Int. 51 (1992) 169-172
12. Turner C.H., and Burr D.B. Basic biomechanical measurements of bone: a tutorial. Bone 14 (1993) 595-608
13. Bouxsein M.L. Mechanisms of osteoporosis therapy: a bone strength perspective. Clin. Cornerstone Suppl. 2 (2002) S13-S21
14. Recker R.R., Weinstein R.S., Chesnut C.H., Schimmer R.C., Hughes C., Bonvoisin B., et al. Histomorphometric evaluation of daily and intermittent oral ibandronate in women with postmenopausal osteoporosis: results from the BONE study. Osteoporos. Int. 15 (2004) 231-237
15. World Health Organization. Guidelines for preclinical evaluation and clinical trials in osteoporosis (1998), WHO, Geneva
16. Bonjour J.P., Ammann P., and Rizzoli R. Importance of preclinical studies in the development of drugs for treatment of osteoporosis: a review related to the 1998 WHO guidelines. Osteoporos. Int. 9 (1999) 379-393
17. Kalu D.N. The ovariectomized rat model of postmenopausal bone loss. Bone Miner. 15 (1999) 175-192
18. Frost H.M., and Jee W.S. On the rat model of human osteoporosis. Bone Miner. 18 (1992) 227-236
19. Ralston S.H., Thiebaud D., Herrmann Z., Steinhauer E.U., Thurlimann B., Walls J., et al. Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia. Br. J. Cancer 75 (1997) 295-300
20. Herrmann Z., and Schoter K.H. The new bisphosphonate ibandronate in the treatment of tumor-induced hypercalcemia. Onkologie 22 (1999) 208-211
21. Body J.J. Dosing regimens and main adverse events of bisphosphonates. Semin. Oncol. 28 Suppl. 11 (2001) 49-53
22. Tripathy D., Budde M., and Bergstrom B. Oral daily ibandronate: an effective and convenient therapy for the reduction of skeletal complications in breast cancer patients with bone metastases (Bondronat MF4434 Study Group). Ann. Oncol. 13 Suppl. 5 (2002) 168
23. Body J.J., Diel I.J., Lichinitser M.R., Kreuser E.D., Dornoff W., Gorbunova V.A., et al. Ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases (MF4265 study group). Ann. Oncol. 14 (2003) 1399-1405
24. Pecherstorfer M. Efficacy and safety of ibandronate in the treatment of neoplastic bone disease. Expert Opin. Pharmacother. 5 (2004) 2341-2350
25. Adami S., and Viapiana O. Ibandronate: new option in the treatment of osteoporosis. Drugs Today (Barc) 39 (2003) 877-886
26. Papapoulos S.E. Ibandronate: a potent new bisphosphonate in the management of postmenopausal osteoporosis. Int. J. Clin. Pract. 57 (2003) 417-422
27. Ringe J.D., Dorst A., Faber H., Ibach K., and Sorenson F. Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study. Osteoporos. Int. 14 (2003) 801-807
28. Grauer A., Heichel S., Knaus J., Dosch E., and Ziegler R. Ibandronate treatment in Paget's disease of bone. Bone 24 Suppl. 5 (1999) 87S-89S
29. Woitge H.W., Oberwittler H., Heichel S., Grauer A., Ziegler R., and Seibel M.J. Short- and long-term effects of ibandronate treatment on bone turnover in Paget disease of bone. Clin. Chem. 46 (2000) 684-690
30. Chesnut C.H., Skag A., Christiansen C., Recker R.R., Stakkesatd J.A., Hoiseth A., et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J. Bone Miner. Res. 19 (2004) 1241-1249
31. Adami S., Felsenberg D., Christiansen C., Robinson J., Lorenc R.S., Mahoney P., et al. Efficacy and safety of ibandronate given by intravenous injection once every 3 months. Bone 34 (2004) 881-889
32. Recker R., Stakkestad J.A., Chesnut C.H., Christiansen C., Skag A., Hoiseth A., et al. Insufficiently dosed intravenous ibandronate injections are associated with suboptimal antifracture efficacy in postmenopausal osteoporosis. Bone 34 (2004) 890-899
33. Recker R.R., Reid D.M., Sambrook P., Hughes C., Ward P., Bonvoisin B., et al. Intermittent intravenous ibandronate injection regimens provide at least equivalent efficacy to daily oral ibandronate: 1-year results from DIVA. Arthritis Rheum. 50 (2004) 4095 (Suppl)
34. Miller P.D., McClung M., Macovei L., Stakkestad J.A., Luckey M., Bonvoisin B., et al. Monthly oral ibandronate therapy in postmenopausal osteoporosis: one-year results from the MOBILE study. J. Bone Miner. Res. 20 (2005) 1315-1322
35. Bauss F., Lalla S., Endele R., and Hothorn L.A. Effects of treatment with ibandronate on bone mass, architecture, biomechanical properties, and bone concentration of ibandronate in ovariectomized aged rats. J. Rheumatol. 29 (2002) 2200-2208
36. Bauss F., Wagner M., and Hothorn L.H. Total administered dose of ibandronate determines its effects on bone mass and architecture in ovariectomized aged rats. J. Rheumatol. 29 (2002) 990-998
37. Monier-Faugere M.C., Friedler R.M., Bauss F., and Malluche H.H. A new bisphosphonate, BM 21.0955, prevents bone loss associated with cessation of ovarian function in experimental dogs. J. Bone Miner. Res. 8 (1993) 1345-1355
38. Monier-Faugere M.C., Geng Z., Paschalis E.P., Qi Q., Arnala I., et al. Intermittent and continuous administration of the bisphosphonate ibandronate in ovariohysterectomized beagle dogs: effects on bone morphometry and mineral properties. J. Bone Miner. Res. 14 (1999) 1768-1778
39. Smith S.Y., Recker R.R., Hannan M., Müller R., and Bauss F. Intermittent intravenous administration of the bisphosphonate ibandronate prevents bone loss and maintains bone strength and quality in ovariectomized cynomolgus monkeys. Bone 32 (2003) 45-55
40. Müller R., Hannan M., Smith S., and Bauss F. Intermittent ibandronate preserves bone quality and bone strength in the lumbar spine after 16 months of treatment in the ovariectomized cynomolgus monkey. J. Bone Miner. Res. 19 (2004) 1787-1796
41. Glueer C.C., Scholz-Ahrens K.E., Timm W., Barkmann R., Delling G., Bauss F., et al. The minipig is a good model for glucocorticoid-induced bone loss and shows efficacy of ibandronate treatments for this disorder. J. Bone Miner. Res. 17 Suppl. 1 (2002) S371
42. Bauss F., and Russell R.G.G. Ibandronate in osteoporosis: preclinical data and rationale for intermittent dosing. Osteoporos. Int. 15 (2004) 423-433
43. Mühlbauer R.C., Bauss F., Schenk R., Janner M., Bosies E., Strein K., et al. BM 21.0955, a potent new bisphosphonate to inhibit bone resorption. J. Bone Miner. Res. 6 (1991) 1003-1011
44. Lalla S., Hothorn L.A., Haag N., Bader R., and Bauss F. Lifelong administration of high doses of ibandronate increases bone mass and maintains bone quality of lumbar vertebrae in rats. Osteoporos. Int. 8 (1998) 97-103
45. Helfenstein A., Scholz-Ahrens K.E., Glueer C.C., et al. Effects of ibandronate on mechanical bone strength in glucocorticoid-induced bone loss in a minipig model. Transactions of the 49th Annual Meeting of the Orthopaedic Research Society 28 (2003) 0418
46. Kurth A.H., Kim S.Z., Sedlmeyer I., Hovy L., and Bauss F. Treatment with ibandronate preserves bone in experimental tumour-induced bone loss. J. Bone Jt. Surg., Br. 82 (2000) 126-130
47. Schultheis L., Ruff C.B., Rastogi S., Bloomfield S., Hogan H.A., Sedarko N., et al. Disuse bone loss in hindquarter suspended rats: partial weightbearing, exercise and ibandronate treatment as countermeasures. J. Gravit. Physiol. 7 (2000) P13-P14
48. Guy J.A., Shea M., Peter C.P., Morrissey R., and Hayes W.C. Continuous alendronate treatment throughout growth, maturation, and aging in the rat results in increases in bone mass and mechanical properties. Calcif. Tissue Int. 53 (1993) 283-288
49. Toolan B.C., Shea M., Myers E.R., Borchers R.E., Seedor J.G., Quartuccio H., et al. Effects of 4-amino-1-hydroxybutylidene bisphosphonate on bone biomechanics in rats. J. Bone Miner. Res. 7 (1992) 1399-1406
50. Katsumata T., Nakamura T., Ohnishi H., and Sakurama T. Intermittent cyclical etidronate treatment maintains the mass, structure and the mechanical property of bone in ovariectomized rats. J. Bone Miner. Res. 10 (1995) 921-931
51. Kippo K., Hannuniemi R., Lauren L., Peng Z., Kuurtamo P., Virtamo T., et al. Effect of clodronate treatment on established bone loss in overiectomized rats. Bone 23 (1998) 333-342
52. Glatt M., Pataki A., Evans G.P., Hornby S.B., and Green J.R. Loss of vertebral bone and mechanical in estrogen-deficient rats is prevented by long-term administration of zoledronic acid. Osteoporos. Int. 15 (2004) 707-715
53. Balena R., Toolan B.C., Shea M., Markatos A., Myers E.R., Lee S.C., et al. The effects of 2-year treatment with the aminobisphosphonate alendronate on bone metabolism, bone histomorphometry, and bone strength in ovariectomized nonhuman primates. J. Clin. Invest. 92 (1993) 2577-2586
54. Borah B., Dufrensne T.E., Chmielewski P.A., Gross G.J., Prenger M.C., and Phipps R.J. Risedronate preserves trabecular architecture and increases bone strength in vertebra of ovariectomized minipigs as measured by three-dimensional microcomputed tomography. J. Bone Miner. Res. 17 (2002) 1139-1147
55. Dempster D.W. Bone microarchitecture and strength. Osteoporos. Int. 14 Suppl. 5 (2003) 54-56
56. Affentranger U., Bauss F., Qin L., Cordey J., McIff T., and Rahn B.A. Mechanical properties of cancellous and cortical bone after long term ibandronate dosing in beagle dogs. Bone 17 (1995) 604
57. Bauss F., Schenk R.K., Hort S., Muller-Beckmann B., and Sponer G. New model for simulation of fracture repair in full-grown beagle dogs: model characterization and results from a long-term study with ibandronate. J. Pharmacol. Toxicol. Methods 50 (2004) 25-34
58. Eberhardt C., Sayer J., Gruner E., Schwartz M., Bauss F., and Kurth A.A. Ibandronate reduced the time of implant osseointegration in a rat model. Bone 30 (2002) 40 (Suppl)
59. Eberhardt C., Raussen W., Thiemann S., Schwarz M., Bauss F., and Kurth A.A. Improved osseointegration and periprosthetic bone volume around cementless metal implants under bisphosphonate treatment (article in German). Z. Orthop. Ihre Grenzgeb. 143 (2005) 645-651
60. Eberhardt C., Schwarz M., and Kurth A.H. High dose treatment of nitrogen-containing bisphosphonate ibandronate is required for osseointegration of cementless metal implants. J. Orthop. Sci. 10 (2005) 622-626
61. Eberhardt C., Stumpf U., Brahnkamp J., Schwarz M., and Kurth A.H. Osseointegration of cementless implants with different bisphosphonate regimens. Clin. Orthop. Relat. Res 447 (2006) 195-200
62. Kurth A.A., Eberhardt C., Müller S., Steinacker M., Schwarz M., and Bauss F. The bisphosphonate ibandronate improves implant integration in osteopenic ovariectomized rats. Bone 37 (2005) 204-210